KSR1 knockout mouse model demonstrates MAPK pathway's key role in cisplatin- and noise-induced hearing loss.

Autor:	Ingersoll MA; Department of Pharmacology and Neuroscience, School of Medicine, Creighton University, Omaha, NE 68178, USA., Lutze RD; Department of Pharmacology and Neuroscience, School of Medicine, Creighton University, Omaha, NE 68178, USA., Kelmann RG; Department of Pharmacology and Neuroscience, School of Medicine, Creighton University, Omaha, NE 68178, USA., Kresock DF; Department of Pharmacology and Neuroscience, School of Medicine, Creighton University, Omaha, NE 68178, USA., Marsh JD; Department of Pharmacology and Neuroscience, School of Medicine, Creighton University, Omaha, NE 68178, USA., Quevedo RV; Department of Biomedical Sciences, School of Medicine, Creighton University, Omaha, NE 68178, USA., Zuo J; Department of Biomedical Sciences, School of Medicine, Creighton University, Omaha, NE 68178, USA., Teitz T; Department of Pharmacology and Neuroscience, School of Medicine, Creighton University, Omaha, NE 68178, USA.
Jazyk:	angličtina
Zdroj:	BioRxiv : the preprint server for biology [bioRxiv] 2023 Nov 13. Date of Electronic Publication: 2023 Nov 13.
DOI:	10.1101/2023.11.08.566316
Abstrakt:	Hearing loss is a major disability in everyday life and therapeutic interventions to protect hearing would benefit a large portion of the world population. Here we found that mice devoid of the protein kinase suppressor of RAS 1 (KSR1) in their tissues (germline KO mice) exhibit resistance to both cisplatin- and noise-induced permanent hearing loss compared to their wild-type KSR1 littermates. KSR1 is expressed in the cochlea and is a scaffold protein that brings in proximity the mitogen-activated protein kinase (MAPK) proteins BRAF, MEK and ERK and assists in their activation through a phosphorylation cascade induced by both cisplatin and noise insults in the cochlear cells. Deleting the KSR1 protein tempered down the MAPK phosphorylation cascade in the cochlear cells following both cisplatin and noise insults and conferred hearing protection of up to 30 dB SPL in three tested frequencies in mice. Treatment with dabrafenib, an FDA-approved oral BRAF inhibitor, downregulated the MAPK kinase cascade and protected the KSR1 wild-type mice from both cisplatin- and noise-induced hearing loss. Dabrafenib treatment did not enhance the protection of KO KSR1 mice, as excepted, providing evidence dabrafenib works primarily through the MAPK pathway. Thus, either elimination of the KSR1 gene expression or drug inhibition of the MAPK cellular pathway in mice resulted in profound protection from both cisplatin- and noise-induce hearing loss. Inhibition of the MAPK pathway, a cellular pathway that responds to damage in the cochlear cells, can prove a valuable strategy to protect and treat hearing loss. Competing Interests: Competing interests: T.T. and J.Z. are inventors on a patent for the use of dabrafenib in hearing protection (US 2020–0093923 A1 and US Patent no 11,433,073, 18794717.1 / EP 3618807, Japan 2022–176126, China 201880029618.7) and are co-founders of Ting Therapeutics LLC. All other authors declare that they have no competing interests.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu